OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
February 02, 2021
New approaches to clinical trials, spurred by the COVID-19 pandemic, have dramatically shortened development timeframes. Can these gains be sustained once conditions return to normal?
Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.
Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.
Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.
February 01, 2021
A unified scale-up approach, as presented here, can be applied to any unit operation.
CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.
With appropriate planning and the proper use of technology, remote auditing can be as effective and informative as in-person auditing.
FDA puts applications on hold as the agency limits alternative oversight methods.
Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, commends the leadership of the pharmaceutical industry in combatting the COVID-19 pandemic.
From the Editor
A complicated vaccination rollout and mixed messages may derail the pandemic endgame